Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of Zostavax before biologic therapy in rheumatoid arthritis
MOH_2017-05-14_000414Phase 4Recruiting
- Sponsor
- ד"ר דבי זיסמן
- Start
- Jan 2017
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of zoster vaccine, live in herpes zoster (HZ) (2 arms), sponsored by ד"ר דבי זיסמן. Primary endpoints: Safety of Zostavax and Tolerability of Zostavax. Started Jan 2017; status: recruiting.
02
Drugs
zoster vaccine, live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on MOH_2017-05-14_000414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-14_000414.